Journal of Clinical Oncology
Articles in this Issue
Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno
Reply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond
PURPOSE Malignant ovarian germ cell tumors (MOGCTs) are rare, aggressive malignancies predominantly affecting young women. Unlike testicular germ cell tumors, prognostic factors ar...
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy
The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during...
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform regi...
Cracks in the Estrogen Carcinogenesis of Breast Cancer
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
PURPOSE Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis, particularly those with human papillomavirus (HPV)–negative d...
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...
Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
PURPOSE Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between...
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial
PURPOSE Neoadjuvant immune checkpoint inhibition has shown promise in localized deficient mismatch repair (dMMR) colorectal cancer, yet the optimal treatment duration, regimen, and...
Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...
Long-Term Efficacy and Safety of Taletrectinib in Patients With <i>ROS1</i> + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study
Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) with activity against the ROS1 G2032R resistance mutation. Initial data from the TRUST-I study (ClinicalT...